Literature DB >> 8267644

Glucuronidation of diflunisal by rat liver microsomes. Effect of microsomal beta-glucuronidase activity.

F M Brunelle1, R K Verbeeck.   

Abstract

The in vitro formation rates of the phenolic (DPG) and acyl (DAG) glucuronides of diflunisal were investigated using rat liver microsomes. Preliminary studies showed that DAG hydrolysed rapidly (T1/2 = 12 min) when incubated in the presence of rat liver microsomes at pH 7.4 and 37 degrees. DPG was much more stable under the same conditions (T1/2 = 35 hr). Hydrolysis of DAG and DPG by rat liver microsomes was inhibited by 4 mM saccharolactone, a beta-glucuronidase inhibitor. The apparent Km and Vmax values for the formation of DAG in the absence and presence of 4 mM D-saccharic acid-1,4-lactone (saccharolactone) were the following: Km = 0.05 +/- 0.02 vs 0.08 +/- 0.02 mM and Vmax = 0.20 +/- 0.06 vs 0.43 +/- 0.07 nmol/min/mg protein (0 and 4 mM saccharolactone, respectively). The significant increase in apparent Vmax for DAG formation in the presence of saccharolactone can be explained by the inhibition of beta-glucuronidase-catalysed hydrolysis of DAG. Apparent Km and Vmax values for the formation rate of DPG were not affected by addition of saccharolactone to the incubation medium. These results indicate that beta-glucuronidase-catalysed hydrolysis of certain glucuronides formed during microsomal incubations may significantly affect the apparent glucuronidation rate due to the presence of a glucuronidation-deglucuronidation cycle.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8267644     DOI: 10.1016/0006-2952(93)90636-b

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

Review 1.  The role of beta-glucuronidase in drug disposition and drug targeting in humans.

Authors:  B Sperker; J T Backman; H K Kroemer
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  Overestimation of flavonoid aglycones as a result of the ex vivo deconjugation of glucuronides by the tissue β-glucuronidase.

Authors:  Qing-Yi Lu; Lifeng Zhang; Guido Eibl; Vay Liang W Go
Journal:  J Pharm Biomed Anal       Date:  2013-10-05       Impact factor: 3.935

3.  Hepatic conjugation/deconjugation cycling pathways. Computer simulations examining the effect of Michaelis-Menten parameters, enzyme distribution patterns, and a diffusional barrier on metabolite disposition.

Authors:  S B Hansel; M E Morris
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

4.  The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.

Authors:  Peter Tobin; Stephen Clarke; J Paul Seale; Soon Lee; Michael Solomon; Sally Aulds; Michael Crawford; James Gallagher; Tony Eyers; Laurent Rivory
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

Review 5.  Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies.

Authors:  Urs A Boelsterli; Matthew R Redinbo; Kyle S Saitta
Journal:  Toxicol Sci       Date:  2012-10-22       Impact factor: 4.849

6.  Effect of the beta-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases.

Authors:  Lauren Oleson; Michael H Court
Journal:  J Pharm Pharmacol       Date:  2008-09       Impact factor: 3.765

7.  Esterase 22 and beta-glucuronidase hydrolyze retinoids in mouse liver.

Authors:  Renate Schreiber; Ulrike Taschler; Heimo Wolinski; Andrea Seper; Stefanie N Tamegger; Maria Graf; Sepp D Kohlwein; Guenter Haemmerle; Robert Zimmermann; Rudolf Zechner; Achim Lass
Journal:  J Lipid Res       Date:  2009-08-31       Impact factor: 5.922

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.